<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04472650</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-Sitravatinib-101</org_study_id>
    <nct_id>NCT04472650</nct_id>
  </id_info>
  <brief_title>Relative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy Adults</brief_title>
  <official_title>A Phase 1, Open-label, Single-dose, Randomized Crossover Study to Evaluate the Relative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to investigate the relative bioavailability and
      pharmacokinetics (PK) of sitravatinib free base and malate salt capsule formulations
      following oral administration in healthy adults.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve (AUC) from time zero to infinity (AUC0-âˆž)</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from time zero to the last quantifiable concentration (AUC0-t)</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of the maximum observed plasma concentration (Tmax)</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent terminal elimination half-life (T1/2)</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent total plasma clearance (CL/F)</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent volume of distribution (Vz/F).</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants experiencing adverse events (AEs)</measure>
    <time_frame>Up to 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants experiencing serious adverse events (SAEs)</measure>
    <time_frame>Up to 8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Tumor</condition>
  <arm_group>
    <arm_group_label>Sitravatinib Free Base + Malate Salt</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: sitravatinib free base capsule on Day 1 of the 15 day cycle
Period 2: sitravatinib malate salt capsule on Day 1 of the 15 day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitravatinib Malate Salt + Free Base</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: sitravatinib malate salt capsule on Day 1 of the 15 day cycle
Period 2: sitravatinib free base capsule on Day 1 of the 15 day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitravatinib</intervention_name>
    <description>Administered as a free base capsule</description>
    <arm_group_label>Sitravatinib Free Base + Malate Salt</arm_group_label>
    <arm_group_label>Sitravatinib Malate Salt + Free Base</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitravatinib</intervention_name>
    <description>Administered as a malate salt capsule</description>
    <arm_group_label>Sitravatinib Free Base + Malate Salt</arm_group_label>
    <arm_group_label>Sitravatinib Malate Salt + Free Base</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Body mass index between 18.0 and 32.0 kg/m2, inclusive.

          2. In good health, determined by no clinically significant findings from medical history,
             physical examination, 12-lead ECG, vital sign measurements, and clinical laboratory
             evaluations at Screening and/or Check-in as assessed by the Investigator (or
             designee).

          3. Are able to swallow multiple capsules.

        Key Exclusion Criteria:

          1. History of stomach or intestinal surgery or resection

          2. Have previously completed or withdrawn from this study or any other study
             investigating sitravatinib, and have previously received the investigational product.

          3. Participants who, in the opinion of the Investigator (or designee), should not
             participate in this study.

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yu Lu, MD</last_name>
    <role>Study Director</role>
    <affiliation>BeiGene</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BeiGene</last_name>
    <phone>+1-877-828-5568</phone>
    <email>clinicaltrials@beigene.com</email>
  </overall_contact>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 14, 2020</study_first_submitted>
  <study_first_submitted_qc>July 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2020</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

